DSM invests in IntegraGen
This article was originally published in The Tan Sheet
Executive Summary
The Netherlands-based firm has invested $2.6 mil. (€1 = $1.28) in IntegraGen, a French biotechnology company specializing in the development and delivery of genetic tests for rapid diagnosis and better treatment of complex diseases, DSM announces Nov. 7. "IntraGen's proprietary GenomeHIP technology platform identifies disease genes by allowing the rapid comparison of genomes of family members affected with the same disease," the release states. IntegraGen also "recognizes the potential of its know-how in personalized nutrition," which has led to a collaboration program in the area of weight management, the release says. Recently, DSM collaborated with the European Genetic Alliances Network and the International Genetic Alliance to promote health management and "the contribution of functional foods ingredients" to patient and consumer organizations (1"The Tan Sheet," Oct. 30, 2006, In Brief)...
You may also be interested in...
DSM preventive health collaboration
DSM Food Specialties is strengthening its work with patient organizations European Genetic Alliances Network (EGAN) and the International Genetic Alliance (IGA) to promote health management and "the contribution of functional food ingredients" to patient and consumer organizations, policy makers and the general public, according to a release from The Delft, The Netherlands-based ingredient firm. "This collaboration will help us gain better insight into patient needs in order to develop products that meet these needs," said Philip Rijken, the head of nutritional science. "Together we aim to further promote evidence-based development of functional food ingredients and nutritional products which are effective in optimizing and maintaining health in general or in reducing chronic/genetic disease risk"...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.